Daxiang Biotech

Daxiang Biotech develops industrial OoC platforms made of biocompatible plastics replacing PDMS to prevent the absorption of small hydrophobic drug molecules.

Country
China
Coverage
CNEUUS
diagnostics-medtech
Regulatorsfdaemanmpa

Verifiable facts

FactValueSource
FundingRaised over CNY 300 million in total funding across multiple rounds (Angel, Series A, and Series B)caplight.com · daxiangbio.cn · daxiangbio.com · preqin.com
CapacityOperates a closed loop that spans platform design, research execution, and industrial production; capacity includes 50+ culture kits and 100+ biomimetic models medium confidencedaxiangbio.cn · lifesciencesreview.com
CertificationGB/T19001-2016/ISO9001:2015 quality management system certification (2022)daxiangbio.cn
Regulatory approvalSupports pharmaceutical firms in IND clearances; models have passed authoritative third-party technical verification, including successful predictions for kidney, intestine, and liver chipsdaxiangbio.cn · lifesciencesreview.com
Production siteBeijing, China (Yiyuan Industrial Base, Haidian District)daxiangbio.com · daxiangbio.cn · lifesciencesreview.com
HeadcountReports of 1 to 4 employees in some professional database listings, though the company describes itself as a leading industrial firm with a complete operational structure medium confidencecaplight.com

Independent sources: caplight.com · lifesciencesreview.com · preqin.com

Technologies
NameClusterRisk
Organoids & organ-on-chipdiagnostics-medtechLow

Compiled by BIOECON from primary sources.

Compliance Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.